Blueprint Medicines (BPMC) Receives a Buy from Robert W. Baird

Robert W. Baird analyst Joel Beatty maintained a Buy rating on Blueprint Medicines (BPMCResearch Report) on August 2 and set a price target of $96.00. The company’s shares closed last Thursday at $64.72.

According to, Beatty is a 3-star analyst with an average return of 2.0% and a 47.8% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Ultragenyx Pharmaceutical, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $86.69 average price target, a 43.4% upside from current levels. In a report issued on August 2, Raymond James also maintained a Buy rating on the stock with a $115.00 price target.

See the top stocks recommended by analysts >>

Based on Blueprint Medicines’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $62.73 million and GAAP net loss of $106 million. In comparison, last year the company earned revenue of $21.58 million and had a GAAP net loss of $99.71 million.

Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Most recently, in May 2022, Nicholas Lydon, a Director at BPMC bought 10,909 shares for a total of $213,053.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Read More on BPMC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed